Johnson & Johnson (JNJ): Long-Term Debt
$41.44B
As of 2025-12-28
+13.4%
3-year compound annual growth
+3.8%
5-year compound annual growth
| Period ended | Long-Term Debt | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-28 | $41.44B | +27.9% | 2026-02-11, Balance as of period end |
| 2024-12-29 | $32.40B | +18.5% | 2026-02-11, Balance as of period end |
| 2023-12-31 | $27.35B | -3.8% | 2025-02-13, Balance as of period end |
| 2023-01-01, Fiscal 2022 | $28.44B | -11.5% | 2024-02-16, Balance as of period end |
| 2022-01-02, Fiscal 2021 | $32.12B | -6.7% | 2023-02-16, Balance as of period end |
| 2021-01-03, Fiscal 2020 | $34.43B | n/a | 2022-02-17, Balance as of period end |
| No annual figure between 2011-01-02 and 2021-01-03. | |||
| 2011-01-02, Fiscal 2010 | $9.17B | +11.0% | 2011-02-25, Balance as of period end |
| 2010-01-03, Fiscal 2009 | $8.26B | n/a | 2011-02-25, Balance as of period end |
Long-Term Debt at similar companies
| Company | Year ended | Long-Term Debt | Change YoY |
|---|---|---|---|
| Johnson & Johnson (JNJ) | 2025-12-28 | $41.44B | +27.9% |
| Eli Lilly & Co (LLY) | 2024-12-31 | $29.47B | +54.3% |
| AbbVie Inc. (ABBV) | 2025-12-31 | $64.50B | -3.5% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $44.83B | -9.3% |
| Abbott Laboratories (ABT) | 2025-12-31 | $12.93B | -8.5% |
| Bausch Health Companies Inc. (BHC) | 2025-12-31 | $20.82B | -3.7% |
| Organon & Co. (OGN) | 2025-12-31 | $8.64B | -2.7% |
| BeOne Medicines Ltd. (ONC) | 2025-12-31 | $836.37M | n/a |
| Elanco Animal Health Inc (ELAN) | 2025-12-31 | $3.76B | -12.9% |
Compare JNJ, LLY, ABBV, BMY side by side · Screen every company in Pharmaceutical Preparations ↗